| Disulfide bond bridge insertion turns hydrophobic anticancer prodrugs into self-assembled nanomedicines Y Wang, D Liu, Q Zheng, Q Zhao, H Zhang, Y Ma, JK Fallon, Q Fu, ... Nano letters 14 (10), 5577-5583, 2014 | 235 | 2014 |
| Low-dose MDMA (“ecstasy”) induces vasopressin secretion JA Henry, JK Fallon, AT Kicman, AJ Hutt, DA Cowan, M Forsling The Lancet 351 (9118), 1784, 1998 | 197 | 1998 |
| Quantification of human uridine-diphosphate glucuronosyl transferase 1A isoforms in liver, intestine, and kidney using nanobore liquid chromatography–tandem mass spectrometry DE Harbourt, JK Fallon, S Ito, T Baba, JK Ritter, GL Glish, PC Smith Analytical chemistry 84 (1), 98-105, 2012 | 190 | 2012 |
| Stereospecific analysis and enantiomeric disposition of 3, 4-methylenedioxymethamphetamine (Ecstasy) in humans JK Fallon, AT Kicman, JA Henry, PJ Milligan, DA Cowan, AJ Hutt Clinical chemistry 45 (7), 1058-1069, 1999 | 173 | 1999 |
| Targeted quantitative proteomics for the analysis of 14 UGT1As and-2Bs in human liver using NanoUPLC–MS/MS with selected reaction monitoring JK Fallon, H Neubert, R Hyland, TC Goosen, PC Smith Journal of proteome research 12 (10), 4402-4413, 2013 | 131 | 2013 |
| Quantitative profiling of human renal UDP-glucuronosyltransferases and glucuronidation activity: a comparison of normal and tumoral kidney tissues G Margaillan, M Rouleau, JK Fallon, P Caron, L Villeneuve, V Turcotte, ... Drug Metabolism and Disposition 43 (4), 611-619, 2015 | 109 | 2015 |
| Combinational delivery of hydrophobic and hydrophilic anticancer drugs in single nanoemulsions to treat MDR in cancer Y Ma, D Liu, D Wang, Y Wang, Q Fu, JK Fallon, X Yang, Z He, F Liu Molecular pharmaceutics 11 (8), 2623-2630, 2014 | 104 | 2014 |
| The effect of 3, 4‐methylenedioxymethamphetamine (MDMA,? ecstasy?) and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus ML Forsling, JK Fallon, D Shah, GS Tilbrook, DA Cowan, AT Kicman, ... British journal of pharmacology 135 (3), 649-656, 2002 | 101 | 2002 |
| Utility of Oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin … JW Higgins, JQ Bao, AB Ke, JR Manro, JK Fallon, PC Smith, ... Drug Metabolism and Disposition 42 (1), 182-192, 2014 | 95 | 2014 |
| Immunization of guinea pigs with novel hepatitis B antigen as nanoparticle aggregate powders administered by the pulmonary route P Muttil, C Prego, L Garcia-Contreras, B Pulliam, JK Fallon, C Wang, ... The AAPS journal 12, 330-337, 2010 | 93 | 2010 |
| Targeted precise quantification of 12 human recombinant uridine-diphosphate glucuronosyl transferase 1A and 2B isoforms using nano-ultra-high-performance liquid chromatography … JK Fallon, H Neubert, TC Goosen, PC Smith Drug Metabolism and Disposition 41 (12), 2076-2080, 2013 | 77 | 2013 |
| Quantification of four efflux drug transporters in liver and kidney across species using targeted quantitative proteomics by isotope dilution NanoLC-MS/MS JK Fallon, PC Smith, CQ Xia, MS Kim Pharmaceutical research 33, 2280-2288, 2016 | 68 | 2016 |
| Action of MDMA (ecstasy) and its metabolites on arginine vasopressin release JK Fallon, D Shah, AT Kicman, AJ Hutt, JA Henry, DA Cowan, M Forsling Annals of the New York Academy of Sciences 965 (1), 399-409, 2002 | 68 | 2002 |
| Absolute quantification of human uridine-diphosphate glucuronosyl transferase (UGT) enzyme isoforms 1A1 and 1A6 by tandem LC-MS JK Fallon, DE Harbourt, SH Maleki, FK Kessler, JK Ritter, PC Smith Drug metabolism letters 2 (3), 210-222, 2008 | 55 | 2008 |
| Arginine vasopressin release in response to the administration of 3, 4-methylenedioxymethamphetamine (“ecstasy”): is metabolism a contributory factor? M Forsling, JK Fallon, AT Kicman, AJ Hutt, DA Cowan, JA Henry Journal of Pharmacy and Pharmacology 53 (10), 1357-1363, 2001 | 54 | 2001 |
| Quantitative characterization of major hepatic UDP-glucuronosyltransferase enzymes in human liver microsomes: comparison of two proteomic methods and correlation with catalytic … B Achour, A Dantonio, M Niosi, JJ Novak, JK Fallon, J Barber, PC Smith, ... Drug Metabolism and Disposition 45 (10), 1102-1112, 2017 | 53 | 2017 |
| Multiplexed targeted quantitative proteomics predicts hepatic glucuronidation potential G Margaillan, M Rouleau, K Klein, JK Fallon, P Caron, L Villeneuve, ... Drug Metabolism and Disposition 43 (9), 1331-1335, 2015 | 51 | 2015 |
| Pulmonary immunization of guinea pigs with diphtheria CRM-197 antigen as nanoparticle aggregate dry powders enhance local and systemic immune responses P Muttil, B Pulliam, L Garcia-Contreras, JK Fallon, C Wang, AJ Hickey, ... The AAPS journal 12, 699-707, 2010 | 51 | 2010 |
| Scaling factors for the in vitro–in vivo extrapolation (IV–IVE) of renal drug and xenobiotic glucuronidation clearance KM Knights, SM Spencer, JK Fallon, N Chau, PC Smith, JO Miners British Journal of Clinical Pharmacology 81 (6), 1153-1164, 2016 | 49 | 2016 |
| Pharmacokinetics of sequential doses of capreomycin powder for inhalation in guinea pigs L Garcia-Contreras, P Muttil, JK Fallon, M Kabadi, R Gerety, AJ Hickey Antimicrobial agents and chemotherapy 56 (5), 2612-2618, 2012 | 44 | 2012 |
